AIVEN
29.11.2022 09:02:41 CET | Business Wire | Press release
Aiven, the open source cloud data platform company, has announced several key senior leadership appointments who collectively are focused on helping deliver the company’s commitment to democratising access to the best open source technologies while reducing the environmental impact of cloud services.
These strategic new leadership roles span operations and strategy, product marketing, developer relations, and product management and include
- Katariina Korhonen, Vice President of Strategy and Operations
- Amy Krishnamohan, Vice President of Product Marketing
- Ian Massingham, Vice President of Developer Relations and Community
- Jonah Kowall, Vice President of Product Management
Oskari Saarenmaa, CEO and Co-founder at Aiven, comments on the appointments. “Aiven’s mission is to make developers’ lives better, by helping them build more sophisticated applications accessible to all. When starting Aiven, our goal was to build the company that we wanted to work for. Today we are delighted to be welcoming such a talented group to our leadership team and our wider Aiven community. Our ability to attract the best talent, while also supporting the career growth of our people continues to be instrumental in helping us develop new platform capabilities that bring us closer towards our goal of building more sustainable applications in the cloud.”
Katariina Korhonen has been appointed Vice President of Strategy and Operations to Aiven's Executive Leadership team. Katariina works closely with other senior executives and the board of directors and is focusing on building out Aiven’s corporate, operations, and sustainability strategy globally. Prior to her new role, Katariina spent the last six years in various executive roles at Smartly.
Amy Krishnamohan has also joined as Vice President of Product Marketing with the responsibility for Aiven’s product marketing direction and strategy, and nurturing and engaging with key stakeholders such as analysts, industry thought leaders, and strategic customers to increase the market awareness of Aiven. A Masters alumna of Carnegie Mellon University, Amy has gained diverse experience across product marketing and marketing strategy where she managed open-source database projects and other cloud-native databases. Prior to joining Aiven, she led product marketing strategies from major database companies such as MariaDB and Google Cloud.
Aiven also welcomes Ian Massingham as the company’s Vice President of Developer Relations and Community focusing on further building Aiven’s relationship with the developer community and ensuring that our programs align with our mission of making developers’ lives better. Prior to joining Aiven, Ian led the Developer Relations & Community team at MongoDB. Before that, he played an integral role in establishing and scaling the evangelism and developer relations function at AWS and led Worldwide Solutions Architecture for Startup customers for the final 18 months of his tenure at AWS.
Jonah Kowall has also joined as Aiven’s new Vice President of Product Management. In his role, Jonah will lead and execute the product strategy and head the product team responsible for platform enhancements to support ongoing growth in Aiven’s customer base. Previously a Chief Technology Officer at Logz.io and several other startups, Jonah’s background includes being a Research VP at Gartner and a regular contributor and maintainer of the Open Source Jaeger and OpenTelemetry projects. Jonah joins Aiven and brings with him a wealth of knowledge on all things “observability”.
This latest announcement of senior leadership expansion closely follows the appointment of Olivier van Grembergen as Regional Vice President (RVP) of Aiven Asia Pacific (APAC), announced earlier in October to drive continued growth in the region.
To learn more about Aiven, please visit https://aiven.io/
Free Trial https://console.aiven.io/signup
About Aiven
Headquartered in Helsinki and with hubs in Berlin, Boston, Paris, Singapore, Sydney, Tokyo, and Toronto, Aiven provides managed open source data technologies, like PostgreSQL, Apache Kafka and OpenSearch, on all major clouds. Through Aiven, developers can do what they do best: create applications. Meanwhile, Aiven does what they do best: manage cloud data infrastructure. Aiven enables customers to drive business results from open source that trigger true transformations far beyond their own backyard. Most recently, Aiven achieved a $3B valuation and has now raised $420M total funding backed by its investors Atomico, Earlybird, Eurazeo, IVP, Lifeline, Salesforce Ventures, and World Innovation Lab.
To learn more about Aiven, visit aiven.io and follow @aiven_io on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom